Last reviewed · How we verify
MDX-1100
At a glance
| Generic name | MDX-1100 |
|---|---|
| Also known as | Anti CXCR4 Monocolonal anti-body, anti-IP-10 |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of MDX-1100 in Subjects With Active Ulcerative Colitis (PHASE2)
- Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA) (PHASE2)
- A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDX-1100 CI brief — competitive landscape report
- MDX-1100 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI